Context Therapeutics: Avidity reports 8.7% stake
Context Therapeutics Inc. ownership update: an amendment to a Schedule 13G/A reports that Avidity-related entities and Michael Gregory hold sizeable shared voting and dispositive positions in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Context Therapeutics Inc. ownership update: an amendment to a Schedule 13G/A reports that Avidity-related entities and Michael Gregory hold sizeable shared voting and dispositive positions in the company. The disclosure lists 8,302,808 shares (representing 8.7%) for several Avidity entities and for Michael Gregory, and 7,364,795 shares (representing 7.7%) for Avidity Private Master Fund I.
The filing states these securities are directly owned by advisory clients of Avidity Partners Management LP and that the holdings are reported as shared voting and shared dispositive powers. Signatures and exhibits include a Joint Filing Agreement and Control Person identification; the filing is signed by Michael Gregory as managing member on 05/12/2026.
Insights
Large passive positions disclosed by Avidity across multiple entities.
Avidity-related entities are shown with 8,302,808 shares and 8.7% ownership in several listings, while Avidity Private Master Fund I holds 7,364,795 shares (7.7%). The filing characterizes these holdings as shared voting and shared dispositive power, indicating collective advisory control rather than sole control.
Cash-flow treatment and sale intentions are not stated in the excerpt; subsequent filings would disclose any changes in position. The reported percentages provide a clear snapshot of institutional concentration as of the amendment.
Joint filing and control-person exhibits standardize attribution across affiliated entities.
The schedule is filed as an amendment (Amendment No. 5) and includes a Joint Filing Agreement and Control Person Identification exhibit. Signatures show Michael Gregory acting as Managing Member across the listed entities, supporting the shared-power disclosures in Item 4.
Because the filing attributes holdings to advisory clients, the governance implication is that voting/dispositive power is exercised collectively through the adviser structure; any change in voting arrangements would require updated disclosures in future filings.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned financial
Joint Filing Agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Avidity report in Context Therapeutics (CNTX)?
Who is reported as the reporting person on the Schedule 13G/A for CNTX?
Does the filing show sole voting or dispositive power for Avidity in CNTX?
AI-generated analysis. How Rhea-AI works. Not financial advice.